.jpg "Enaksha Wickremsinhe, PhD photo")
Senior Director
Eli Lilly and Company
Indianapolis, Indiana
Enaksha is a Senior Director at Eli Lilly and Company. He has over 20 years of bioanalytical experience in quantitative LC/MS/MS supporting all phases of drug development (discovery through clinical development). He is responsible for all scientific and regulatory aspects of bioanalysis supporting the entire small molecule portfolio (nonclinical GLP studies, clinical studies, fit-for-purpose). His expertise also includes microsampling (preclinical and clinical studies), patient centric sampling, pediatric studies, and blood sampling for decentralized clinical trials. Enaksha has also served as an ADME project leader and been responsible for both preclinical and clinical development of several oncology assets including abemaciclib (Verzenio®), baricitinib (Olumiant®) and selpercatinib (Retevmo™). He is the recipient of several awards from Eli Lilly and Company, including the President’s award, the Global 3Rs award, the Innovator award, and the Pediatric Excellence award. Enaksha received his Ph.D. from the Pennsylvania State University. He is the past co-chair of the AAPS Bioanalytical community and current co-chair of the AAPS Microsampling and Patient Centric Sampling subgroup. He is also a member of the ICH M10 Expert Working Group, representing PhRMA.
Disclosure information not submitted.
Tuesday, October 18, 2022
10:30 AM – 11:00 AM ET
Wednesday, October 19, 2022
3:00 PM – 3:15 PM ET